VIE/GMAB (VIE/GMAB)

Vienna Stock Exchange: VIE/GMAB · EUR

€516

+115.70 (+28.9%)· Recorded snapshot

Market cap	30.3B
Revenue (ttm)	3.6B
Net income (ttm)	689.7M
EPS (ttm)	€11.1
P/E (trailing)	46.6x
P/E (forward)	32.7x
Volume	33

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.6B
Net income (ttm): 689.7M
EPS (ttm): €11.1
P/E (trailing): 46.6x
P/E (forward): 32.7x
Market cap: 30.3B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/E32.7

P25 14.3P50 18.7P75 25.4

Trailing P/E46.6

P25 20.4P50 26.7P75 39.7

ROE14

P25 4.8P50 10.6P75 20.1

ROIC12.1

P25 5.8P50 9.5P75 18.2

Benchmarks · 1M

All VIE/GMAB indicators

Market & fundamental data

Available fields

231

Groups with data

Currency

USD

Showing 231 of 231 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Denmark
Country code	AT
Earnings date	2026-11-05
Employees	3,119
Employees change	480
Employees growth	18.19%
Enterprise value	EUR 33.6B
Exchange	Vienna Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1998
Industry	Biotechnology
Is primary listing	No
ISIN number	DK0010272202
Last earnings date	2026-08-06
Last refreshed	2026-10-29
Market cap	EUR 30.3B
Next earnings date	2026-11-05
Price	EUR 515.80
Price currency	EUR
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	vie/GMAB
Website	https://www.genmab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	41.3x
Average P/E ratio (3Y)	20.4x
Average P/E ratio (5Y)	30.26x
Earnings yield	2.15%
EV/Earnings	48.68x
EV/EBIT	28.75x
EV/EBITDA	27.51x
EV/FCF	44.14x
EV/Sales	9.28x
FCF / EV yield	2.27%
FCF yield	2.51%
Forward P/E	32.69x
Graham number	153.23778
Graham upside	-70.29%
Lynch fair value	EUR 170.17
Lynch upside	-67.01%
P/(FCF - SBC) ratio	48.52x
P/(OCF - SBC) ratio	47.06x
P/B ratio	5.81x
P/E ratio	46.57x
P/FCF ratio	39.81x
P/OCF ratio	38.82x
P/S ratio	8.37x
Price/EBITDA ratio	25.12x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	32.29%
EBITDA margin	33.33%
Effective tax rate	13.02%
FCF margin	20.56%
Gross margin	93.03%
Operating margin	32.29%
Pretax margin	21.93%
Profit margin	19.08%
Profit per employee	EUR 221,140
Profitable quarters	35
Profitable years	13
Revenue per employee	EUR 1.2M
ROA	8.79%
ROA (5Y)	10.27%
ROCE	11.73%
ROE	14%
ROE (5Y)	18.28%
ROIC	12.07%
ROIC (5Y)	66.47%
SBC / revenue	3.78%
Tax / revenue	2.86%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-36.79%
EPS growth (Q)	-9.41%
EPS growth (QoQ)	491.57%
EPS growth 10Y	22.48%
EPS growth 3Y	7.05%
EPS growth 5Y	15.83%
EPS growth years	0
FCF growth	-12.75%
FCF growth (Q)	-5.77%
FCF growth 3Y	1.65%
FCF growth 5Y	-0.57%
Gross profit growth	20.39%
Gross profit growth (Q)	23.39%
Gross profit growth 3Y	17.39%
Gross profit growth 5Y	26.91%
Net income growth	-37.9%
Net income growth (Q)	-9.82%
Net income growth (QoQ)	471.7%
Net income growth 3Y	5.02%
Net income growth 5Y	14.48%
Net income growth years	0
OCF growth	-14.08%
OCF growth (Q)	-17.74%
OCF growth (QoQ)	1,600%
OCF growth 10Y	26.01%
OCF growth 3Y	0.23%
OCF growth 5Y	-0.81%
Operating income growth	13.53%
Operating income growth (Q)	13.06%
Operating income growth 3Y	12.28%
Operating income growth 5Y	22.07%
Revenue growth	22.26%
Revenue growth (Q)	24.87%
Revenue growth (QoQ)	28.91%
Revenue growth 10Y	35%
Revenue growth 3Y	20.2%
Revenue growth 5Y	28.76%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -19.3M
Depreciation and amortization	EUR 38.5M
EBIT	EUR 1.2B
EBITDA	EUR 1.2B
EPS	EUR 11.08
Financing cash flow	EUR 4.3B
Free cash flow	EUR 760.6M
Free cash flow minus SBC	EUR 624.1M
Gross profit	EUR 3.4B
Income taxes	EUR 103.3M
Investing cash flow	EUR -4.9B
Net borrowing	EUR 4.8B
Net cash flow	EUR 181.2M
Net income	EUR 689.7M
Operating cash flow minus SBC	EUR 643.3M
Operating income	EUR 1.2B
Revenue	EUR 3.6B
Stock-based compensation	EUR 136.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.91
Book value per share	EUR 87.34
Debt / EBITDA	3.78
Debt / equity	0.89
Debt / FCF	6.07
Goodwill	EUR 318M
Interest coverage	4.96
Long-term assets	EUR 8.4B
Long-term liabilities	EUR 4.7B
Net cash (debt)	EUR -3.3B
Net cash / market cap	-10.88%
Net debt / EBITDA	2.73
Net debt / equity	0.63
Net debt / FCF	4.33
Piotroski F-Score	4
Property, plant and equipment	EUR 227.5M
Shareholders' equity	EUR 5.2B
Tangible book value	EUR -2.9B
Tangible book value per share	EUR -47.94
Total assets	EUR 11B
Total cash	EUR 1.3B
Total debt	EUR 4.6B
Total liabilities	EUR 5.7B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.44
Current assets	EUR 2.5B
Current liabilities	EUR 1B
Current ratio	2.46
Inventory turnover	18.58
Net working capital	EUR 405.3M
Quick ratio	2.44
Working capital	EUR 1.5B
Working capital turnover	1.46

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.73%
Shareholder yield	1.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 262.99
1D price change	28.92%
1M price change	69.06%
1M total return	69.06%
1W price change	50.56%
1W total return	50.56%
1Y price change	105.83%
1Y return CAGR	105.93%
1Y total return	105.83%
20-day SMA	EUR 344.58
200-day SMA	EUR 260.15
3M price change	102.43%
3M total return	102.43%
3Y price change	91.11%
3Y return CAGR	24.09%
3Y total return	91.11%
50-day SMA	EUR 313.53
50-day SMA vs 200-day SMA	50over200
52-week high	EUR 515.80
52-week high date	2026-10-28
52-week low	EUR 203.90
52-week low date	2026-06-03
5Y price change	32.09%
5Y return CAGR	5.72%
5Y total return	32.09%
6M price change	126.03%
6M total return	126.03%
All-time high	EUR 515.80
All-time high date	2026-10-28
All-time low	EUR 156.45
All-time low date	2025-04-09
Average true range (ATR)	EUR 18.14
Average volume	1.7
Change from 52-week high	0%
Change from 52-week low	152.97%
Change from all-time high	0%
Change from all-time low	229.69%
Change from open	28.12%
Day's gap	0.62%
Dollar volume	EUR 17,021
High price	EUR 515.80
Low price	EUR 401.40
Monthly RSI	80.96
Open price	EUR 402.60
Position in 52-week range	100%
Previous close	EUR 400.10
Price vs 150-day SMA	96.13%
Price vs 20-day SMA	49.69%
Price vs 200-day SMA	98.27%
Price vs 50-day SMA	64.51%
Relative volume	20
RSI	90.6
Sharpe ratio	1.71
Sharpe ratio (3Y)	0.66
Sharpe ratio (5Y)	0.21
Sortino ratio	3.56
Sortino ratio (3Y)	1.21
Sortino ratio (5Y)	0.48
Volume	33
Weekly RSI	91.13
YTD price change	89.15%
YTD total return	89.15%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55.3M
Shares change (QoQ)	-3.36%
Shares change (YoY)	-1.73%
Shares held by insiders	1.21%
Shares held by institutions	62.73%

Deeper analysis on VIE/GMAB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VIE/GMAB report

Is a complete VIE/GMAB research report available?

No complete published report is available for vie/GMAB (VIE/GMAB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

VIE/GMAB (VIE/GMAB)

Price

Financial snapshot

Fair-value bridge

Latest news · VIE/GMAB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VIE/GMAB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VIE/GMAB

Frequently asked questions